FRESENIUS KABI AND SANDOZ TO COOPERATE IN THE DEVELOPMENT OF AN HESYLATED BIOPHARMACEUTICAL DRUG

In the agreement, Fresenius Kabi will license its proprietary HESylation technology to Sandoz. This technology platform is based on hydroxyethyl starch (HES) and enables the targeted modification of drugs by coupling HES to an active ingredient. This type of modification may be used to extend the half-life and improve the safety profile of a drug. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5999/101/)